FindTrial
Sign In

Navtemadlin 25-15

DRUG2 trials

Sponsors

Kartos Therapeutics Inc.

Conditions

Or Post–Essential Thrombocythemia MF (Post-ET-MF)Post–Polycythemia Vera MF (Post–PV-MF)Primary Myelofibrosis (PMF)Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) With Intermediate Or High-Risk TP53 Wild-Type (TP53 WT) Who Are Relapsed Or Refractory to Janus Kinase (JAK) - Inhibitor Treatment

Phase 1

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post PV MF), Or Post Essential Thrombocythemia MF (Post ET MF) Who Have a Suboptimal Response to Ruxolitinib
Active, not recruitingCTIS2024-514468-26-00
Kartos Therapeutics Inc.Or Post–Essential Thrombocythemia MF (Post-ET-MF), Post–Polycythemia Vera MF (Post–PV-MF), Primary Myelofibrosis (PMF)
Start: 2020-12-04Target: 13Updated: 2025-07-08

Phase 2

A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects with Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment
Active, not recruitingCTIS2024-513912-89-00
Kartos Therapeutics Inc.Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) With Intermediate Or High-Risk TP53 Wild-Type (TP53 WT) Who Are Relapsed Or Refractory to Janus Kinase (JAK) - Inhibitor Treatment
Start: 2018-12-13Target: 253Updated: 2025-09-17